biostudies-literatureUnknown18(1)Mahboub BMTanta University<h4>Background</h4>Chronic kidney disease (CKD) is a devastating progressive condition accompanied with high morbidity and mortality rates. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have recently proven their renoprotective effects, whereas evidence for metformin remains limited but suggestive of potential benefit. This study aimed at comparing the efficacy and safety of metformin versus empagliflozin, a SGLT2 inhibitor, on retarding CKD progression with exploring supposed mechanistic pathways in clinical settings.<h4>Methods</h4>In this 12-month randomized controlled trial, 120 moderate CKD patients were randomized into three groups: metformin 1000 mg/day (n = 40) or empagliflozin 10 mg/day (n = 40), both added orally to standard treatment, or control who continued standard of carDiabetology & metabolic syndrome17https://www.ebi.ac.uk/biostudies/studies/S-EPMC12801430biostudies-literatureEfficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial.PMC12801430Refaie AFMahboub BMHafez YMEl-Haggar SMMostafa TMfalseEfficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial.<h4>Background</h4>Chronic kidney disease (CKD) is a devastating progressive condition accompanied with high morbidity and mortality rates. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have recently proven their renoprotective effects, whereas evidence for metformin remains limited but suggestive of potential benefit. This study aimed at comparing the efficacy and safety of metformin versus empagliflozin, a SGLT2 inhibitor, on retarding CKD progression with exploring supposed mechanistic pathways in clinical settings.<h4>Methods</h4>In this 12-month randomized controlled trial, 120 moderate CKD patients were randomized into three groups: metformin 1000 mg/day (n = 40) or empagliflozin 10 mg/day (n = 40), both added orally to standard treatment, or control who continued standard of car2025-01-01T00:00:00Z2025 Dec2026-07-15T13:33:02.223Z2026-07-05T03:08:48.354ZS-EPMC128014304137301310.1186/s13098-025-02040-9